Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 2
1958 1
1959 1
1960 1
1965 5
1966 2
1967 1
1968 2
1969 2
1970 3
1971 3
1972 3
1973 4
1974 7
1975 124
1976 109
1977 140
1978 152
1979 140
1980 169
1981 225
1982 259
1983 242
1984 320
1985 271
1986 302
1987 319
1988 333
1989 349
1990 403
1991 418
1992 454
1993 423
1994 417
1995 474
1996 433
1997 444
1998 479
1999 488
2000 525
2001 550
2002 566
2003 586
2004 624
2005 717
2006 673
2007 660
2008 759
2009 816
2010 859
2011 971
2012 1025
2013 1105
2014 1174
2015 1178
2016 818
2017 644
2018 1050
2019 1085
2020 1156
2021 1341
2022 1269
2023 989
2024 110

Text availability

Article attribute

Article type

Publication date

Search Results

26,753 results

Results by year

Filters applied: . Clear all
Page 1
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, van Nimwegen M, Lau SP, Latupeirissa K, Schetters S, van Kooyk Y, Boon L, Moyaart A, Mueller YM, Katsikis PD, Eggermont AM, Vroman H, Stadhouders R, Hendriks RW, Thüsen JV, Grünhagen DJ, Verhoef C, van Hall T, Aerts JG. Dammeijer F, et al. Among authors: van hall t. Cancer Cell. 2020 Nov 9;38(5):685-700.e8. doi: 10.1016/j.ccell.2020.09.001. Epub 2020 Oct 1. Cancer Cell. 2020. PMID: 33007259 Free article.
Here we show in mouse tumor models that tumor-draining lymph nodes (TDLNs) are enriched for tumor-specific PD-1(+) T cells which closely associate with PD-L1(+) cDCs. TDLN-targeted PD-L1-blockade induces enhanced anti-tumor T cell immunity by seeding the tumor site …
Here we show in mouse tumor models that tumor-draining lymph nodes (TDLNs) are enriched for tumor-specific PD-1(+) T cells which clos …
Neoantigen-specific CD4(+) T cells in human melanoma have diverse differentiation states and correlate with CD8(+) T cell, macrophage, and B cell function.
Veatch JR, Lee SM, Shasha C, Singhi N, Szeto JL, Moshiri AS, Kim TS, Smythe K, Kong P, Fitzgibbon M, Jesernig B, Bhatia S, Tykodi SS, Hall ET, Byrd DR, Thompson JA, Pillarisetty VG, Duhen T, McGarry Houghton A, Newell E, Gottardo R, Riddell SR. Veatch JR, et al. Among authors: hall et. Cancer Cell. 2022 Apr 11;40(4):393-409.e9. doi: 10.1016/j.ccell.2022.03.006. Cancer Cell. 2022. PMID: 35413271 Free PMC article.
We used single-cell RNA sequencing and T cell receptor sequences to identify signatures and functional correlates of tumor-specific CD4(+) T cells infiltrating human melanoma. ...The frequency of CXCL13(+) CD4(+) T cells in the tumor correlated with the trans …
We used single-cell RNA sequencing and T cell receptor sequences to identify signatures and functional correlates of tumor-specific C …
Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma.
Zakeri N, Hall A, Swadling L, Pallett LJ, Schmidt NM, Diniz MO, Kucykowicz S, Amin OE, Gander A, Pinzani M, Davidson BR, Quaglia A, Maini MK. Zakeri N, et al. Among authors: hall a. Nat Commun. 2022 Mar 16;13(1):1372. doi: 10.1038/s41467-022-29012-1. Nat Commun. 2022. PMID: 35296658 Free PMC article.
Immunotherapy is now the standard of care for advanced hepatocellular carcinoma (HCC), yet many patients fail to respond. A major unmet goal is the boosting of T-cells with both strong HCC reactivity and the protective advantages of tissue-resident memory T-cells ( …
Immunotherapy is now the standard of care for advanced hepatocellular carcinoma (HCC), yet many patients fail to respond. A major unmet goal …
Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, Su L, Wu X, Zhou J, Mackay S, Kramer J, Duan Z, Yang H, Kolluri A, Hummer AM, Torres MB, Zhu H, Hall MD, Luo X, Chen J, Wang Q, Abate-Daga D, Dropulic B, Hewitt SM, Orentas RJ, Greten TF, Ho M. Li D, et al. Among authors: hall md. Gastroenterology. 2020 Jun;158(8):2250-2265.e20. doi: 10.1053/j.gastro.2020.02.011. Epub 2020 Feb 12. Gastroenterology. 2020. PMID: 32060001 Free PMC article.
Mice injected with CAR (hYP7) T cells had persistent expansion of T cells and subsets of polyfunctional CAR T cells via antigen-induced selection. These T cells were observed in the tumor microenvironment and spleen for up to 7 weeks after CAR T …
Mice injected with CAR (hYP7) T cells had persistent expansion of T cells and subsets of polyfunctional CAR T cells via …
Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression.
Dolina JS, Lee J, Brightman SE, McArdle S, Hall SM, Thota RR, Zavala KS, Lanka M, Ramamoorthy Premlal AL, Greenbaum JA, Cohen EEW, Peters B, Schoenberger SP. Dolina JS, et al. Among authors: hall sm. J Clin Invest. 2023 Sep 1;133(17):e164258. doi: 10.1172/JCI164258. J Clin Invest. 2023. PMID: 37655661 Free PMC article.
Therapeutic benefit to immune checkpoint blockade (ICB) is currently limited to the subset of cancers thought to possess a sufficient tumor mutational burden (TMB) to allow for the spontaneous recognition of neoantigens (NeoAg) by autologous T cells. We explored whether th …
Therapeutic benefit to immune checkpoint blockade (ICB) is currently limited to the subset of cancers thought to possess a sufficient tumor …
A human CD137PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade.
Geuijen C, Tacken P, Wang LC, Klooster R, van Loo PF, Zhou J, Mondal A, Liu YB, Kramer A, Condamine T, Volgina A, Hendriks LJA, van der Maaden H, Rovers E, Engels S, Fransen F, den Blanken-Smit R, Zondag-van der Zande V, Basmeleh A, Bartelink W, Kulkarni A, Marissen W, Huang CY, Hall L, Harvey S, Kim S, Martinez M, O'Brien S, Moon E, Albelda S, Kanellopoulou C, Stewart S, Nastri H, Bakker ABH, Scherle P, Logtenberg T, Hollis G, de Kruif J, Huber R, Mayes PA, Throsby M. Geuijen C, et al. Among authors: hall l. Nat Commun. 2021 Jul 21;12(1):4445. doi: 10.1038/s41467-021-24767-5. Nat Commun. 2021. PMID: 34290245 Free PMC article.
Here we describe a human CD137xPD-L1 bispecific antibody, MCLA-145, identified through functional screening of agonist- and immune checkpoint inhibitor arm combinations. MCLA-145 potently activates T cells at sub-nanomolar concentrations, even under suppressive conditions, …
Here we describe a human CD137xPD-L1 bispecific antibody, MCLA-145, identified through functional screening of agonist- and immune checkpoin …
CD4(+)CD25(+) T regulatory cells in renal transplantation.
Cheung J, Zahorowska B, Suranyi M, Wong JKW, Diep J, Spicer ST, Verma ND, Hodgkinson SJ, Hall BM. Cheung J, et al. Among authors: hall bm. Front Immunol. 2022 Nov 8;13:1017683. doi: 10.3389/fimmu.2022.1017683. eCollection 2022. Front Immunol. 2022. PMID: 36426347 Free PMC article. Review.
Treg represent <10% of peripheral CD4(+)T cells and do not markedly increase in tolerant hosts. CD4(+)CD25(+)Foxp3(+)T cells include both resting and activated Treg that can be distinguished by several markers, many of which are also expressed by effector T …
Treg represent <10% of peripheral CD4(+)T cells and do not markedly increase in tolerant hosts. CD4(+)CD25(+)Foxp3(+)T cell …
Transplant Tolerance, Not Only Clonal Deletion.
Hall BM, Verma ND, Tran GT, Hodgkinson SJ. Hall BM, et al. Front Immunol. 2022 Apr 21;13:810798. doi: 10.3389/fimmu.2022.810798. eCollection 2022. Front Immunol. 2022. PMID: 35529847 Free PMC article. Review.
Third, we review research on alloantigen specific inhibitory T cells that led to the first identification of the CD4(+)CD25(+)T regulatory cell. The key role of T cell derived cytokines, other than IL-2, in promoting survival and expansion of antigen specific …
Third, we review research on alloantigen specific inhibitory T cells that led to the first identification of the CD4(+)CD25(+)T …
Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients.
Hall MS, Teer JK, Yu X, Branthoover H, Snedal S, Rodriguez-Valentin M, Nagle L, Scott E, Schachner B, Innamarato P, Hall AM, Blauvelt J, Rich CJ, Richards AD, Ceccarelli J, Langer TJ, Yoder SJ, Beatty MS, Cox CA, Messina JL, Abate-Daga D, Mule JJ, Mullinax JE, Sarnaik AA, Pilon-Thomas S. Hall MS, et al. Among authors: hall am. J Immunother Cancer. 2023 Oct;11(10):e007288. doi: 10.1136/jitc-2023-007288. J Immunother Cancer. 2023. PMID: 37802604 Free PMC article.
RESULTS: We discovered that neoantigen-specific TIL clones were predominantly CD4(+) T cells and were present in both therapeutic responders and non-responders. CD4(+) TIL demonstrated an effector T cell response with cytotoxicity toward autologous tumor in a major …
RESULTS: We discovered that neoantigen-specific TIL clones were predominantly CD4(+) T cells and were present in both therapeutic res …
Antigen-Specific CD4 T Cell and B Cell Responses to Borrelia burgdorferi.
Hammond EM, Olsen KJ, Ram S, Tran GVV, Hall LS, Bradley JE, Lund FE, Samuels DS, Baumgarth N. Hammond EM, et al. Among authors: hall ls. J Immunol. 2023 Sep 15;211(6):994-1005. doi: 10.4049/jimmunol.2200890. J Immunol. 2023. PMID: 37556156
Yet, a lack of reagents has limited investigations into B. burgdorferi-specific T and B cells. We attempted two approaches to track B. burgdorferi-induced CD4 T cells. ...Although up to 30% of Arp-specific CD4 T cells were ICOS+PD-1+CXCR5+BCL6+ T folli …
Yet, a lack of reagents has limited investigations into B. burgdorferi-specific T and B cells. We attempted two approaches to track B …
26,753 results
You have reached the last available page of results. Please see the User Guide for more information.